X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2726) 2726
science & technology (2300) 2300
life sciences & biomedicine (2188) 2188
erlotinib hydrochloride (2036) 2036
oncology (1632) 1632
lung neoplasms - drug therapy (1608) 1608
female (1475) 1475
quinazolines - therapeutic use (1446) 1446
carcinoma, non-small-cell lung - drug therapy (1370) 1370
male (1318) 1318
erlotinib (1215) 1215
middle aged (1178) 1178
protein kinase inhibitors - therapeutic use (1080) 1080
aged (1073) 1073
antineoplastic agents - therapeutic use (950) 950
receptor, epidermal growth factor - antagonists & inhibitors (926) 926
adult (767) 767
lung neoplasms - pathology (741) 741
antineoplastic combined chemotherapy protocols - therapeutic use (715) 715
treatment outcome (698) 698
mutation (695) 695
lung neoplasms - genetics (665) 665
receptor, epidermal growth factor - genetics (643) 643
quinazolines - administration & dosage (625) 625
carcinoma, non-small-cell lung - pathology (551) 551
cancer (547) 547
lung cancer (545) 545
carcinoma, non-small-cell lung - genetics (522) 522
aged, 80 and over (517) 517
lung cancer, non-small cell (506) 506
epidermal growth factor (496) 496
quinazolines - adverse effects (464) 464
care and treatment (451) 451
erlotinib hydrochloride - therapeutic use (436) 436
chemotherapy (411) 411
animals (400) 400
disease-free survival (399) 399
gefitinib (395) 395
adenocarcinoma - drug therapy (393) 393
quinazolines - pharmacology (364) 364
respiratory system (362) 362
cell line, tumor (360) 360
neoplasm staging (333) 333
lung neoplasms - mortality (325) 325
non-small cell lung cancer (319) 319
respiratory tract diseases (311) 311
receptor, epidermal growth factor - metabolism (306) 306
hematology, oncology and palliative medicine (299) 299
carcinoma, non-small-cell lung - mortality (297) 297
pharmacology & pharmacy (294) 294
prognosis (294) 294
antibodies, monoclonal, humanized (282) 282
research (277) 277
egfr (273) 273
analysis (271) 271
epidermal growth factor receptor (271) 271
tyrosine (268) 268
antineoplastic agents - pharmacology (267) 267
protein kinase inhibitors - pharmacology (267) 267
protein kinase inhibitors - adverse effects (265) 265
mice (253) 253
deoxycytidine - analogs & derivatives (251) 251
survival rate (240) 240
erlotinib hydrochloride - administration & dosage (239) 239
bevacizumab (238) 238
retrospective studies (232) 232
antibodies, monoclonal - therapeutic use (228) 228
antineoplastic agents - adverse effects (227) 227
cetuximab (225) 225
protein kinase inhibitors - administration & dosage (221) 221
medicine & public health (214) 214
erbb receptors - genetics (212) 212
drug therapy (210) 210
erbb receptors - antagonists & inhibitors (209) 209
pancreatic neoplasms - drug therapy (205) 205
kinases (201) 201
metastasis (200) 200
tumors (197) 197
antineoplastic combined chemotherapy protocols - adverse effects (196) 196
disease progression (196) 196
survival analysis (196) 196
lung neoplasms - metabolism (194) 194
cancer therapies (193) 193
deoxycytidine - administration & dosage (192) 192
pulmonary/respiratory (192) 192
drug resistance, neoplasm (191) 191
health aspects (187) 187
adenocarcinoma - pathology (184) 184
adenocarcinoma - genetics (182) 182
clinical trials (181) 181
neoplasms (179) 179
epidermal growth factor receptors (177) 177
nsclc (177) 177
erlotinib hydrochloride - pharmacology (174) 174
kaplan-meier estimate (173) 173
clinical trials as topic (160) 160
antineoplastic agents - administration & dosage (159) 159
genetic aspects (159) 159
follow-up studies (158) 158
carcinoma, non-small-cell lung - metabolism (157) 157
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2714) 2714
French (51) 51
Japanese (41) 41
Chinese (39) 39
German (30) 30
Spanish (10) 10
Czech (7) 7
Hungarian (7) 7
Portuguese (5) 5
Dutch (4) 4
Danish (3) 3
Korean (2) 2
Norwegian (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Polish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
by Wu, Y.-L and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 02/2008, Volume 15, Issue 5, pp. 422 - 432
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
European urology, ISSN 0302-2838, 03/2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Index Medicus | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Cancer discovery, ISSN 2159-8290, 06/2011, Volume 1, Issue 1, pp. 78 - 89
Journal Article